Top Markets
Coin of the day
National Graphite Corp. National Graphite Corp.

National Graphite Corp.

NGRC
주식 순위 #35948
National Graphite Corp. (NGRC), operating through its subsidiary Biotech... National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
주가
$0.021
마지막 동기화: 2026-08-13
시가총액
$3.24M
변동 (1일)
0.00%
변동 (1년)
-46.15%
국가
US
거래 National Graphite Corp. (NGRC)
National Graphite Corp. (NGRC)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
National Graphite Corp.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
National Graphite Corp.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율